News

Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing
Discover key takeaways from Talphera's Q1 2025 Earnings Call! Learn about FDA protocol changes, financial updates, and progress on the NEPHRO CRRT study.
Cytosorbents outlines plans for DrugSorb-ATR appeal and targets breakeven core business by second half 2025
Q1 2025 Management View CEO Phillip Chan reported that CytoSorbents is focused on three main areas: the performance and growth catalysts of the core CytoSorb business, regulatory status and plans for ...